affinity for M 1 -and M 3 -receptor subtypes than the M 2 -receptor subtype (4) , which allowed it to regulate acetylcholine release by inhibiting the prejunctional M 1 subtype and inhibit bladder contraction by blocking the postsynaptic M 3 subtype. Further studies revealed that imidafenacin exhibited functional selectivity toward the bladder over the salivary gland and had a negligible pharmacological effect on the CNS even at high doses (5, 6) . Imidafenacin is known to be a well-tolerated agent in clinical settings and causes fewer adverse effects (7, 8) . Masumori (9) , Takeuchi et al. (10) , and Maggiore et al. (11) recently reviewed the long-term efficacy, safety, and tolerability of imidafenacin and reported a reduced incidence of severe adverse events such as dry mouth and constipation. In addition, imidafenacin can be used safely for a long period of time even by cognitively vulnerable elderly patients with the symptoms of OAB. Thus, it is highly likely that imidafenacin is a safe, efficacious, and tolerable treatment that can control the symptoms of OAB even in the long term.
Yamada et al. (6) and Seki et al. (12) examined the competitive inhibitory effect of imidafenacin on [Nmethyl- 3 H]scopolamine methyl chloride (NMS) binding and revealed that it was a potent inhibitor of muscarinic receptor binding sites in rat and human bladders. Thus, investigating the direct binding properties of imidafenacin to bladder muscarinic receptors is of importance. The aim of the current study was to characterize the binding properties of the new tritium ([ 
Materials and Methods

Materials
[ 3 H]Imidafenacin [4-(2-methyl-1H-imidazol-1-yl)-2- phenyl-2-(3-tritiophenyl)-
Patients and specimens
Human urinary bladder specimens were collected from 12 patients (10 men and 2 women; aged 73.9 ± 5.4, age range 63 -80 years) undergoing total cystectomy for bladder carcinoma. All patients were screened by their physician and were confirmed to exhibit no symptoms of OAB or bladder outlet obstruction. Exclusion criteria included previous pelvic radiotherapy, extensive chemotherapy, current urinary tract infection, or concomitant carcinoma in situ (CIS). Human normal parotid gland specimens were obtained from 5 patients (3 men and 2 women; age: 75.4 ± 4.7, age range: 69 -80 years of age) undergoing the surgical excision of a parotid tumor. None of the patients had diseases or used medications known to interfere with the cholinergic receptor system. Written informed consent was obtained from all patients. This study was conducted according to the Helsinki Declaration, and the protocol of this study was approved by the Ethics Committees of the University of Shizuoka, University of Yamanashi, and Hamamatsu University School of Medicine.
All human bladder specimens were obtained from macroscopically normal tissue in the anterior or lateral wall of the urinary bladder body as described previously (13) . They were immediately transported to the laboratory, and the adventitia and connecting fatty tissues were removed. All specimens of the human normal parotid gland were taken from areas macroscopically free of tumors (14) . They were then stored at −80°C until used. •min −1 (n = 3, mean ± S.E.M.), respectively. Dissociation after the addition of 0.1 mM atropine was also rapid at 25°C, and dissociation rate constants (k −1 ) were calculated as 7.09 ± 1.02 × 10 −2 min (Fig. 3) . Their pK i values are shown in Table 1 , and the rank order of these agents in terms of affinity for binding sites in the bladder was imidafenacin > oxybutynin, tolterodine > solifenacin. The muscarinic binding affinities of imidafenacin in the bladder and parotid gland were 73 and 35 times more potent, respectively, than that of solifenacin. No significant difference was observed in the pK i values of antimuscarinic agents between the bladder and parotid gland ( Table 1 ). The Hill coefficients for their inhibition of specific [ 3 H]imidafenacin binding in both tissues were close to unity.
Discussion
Imidafenacin was previously shown to be a welltolerated therapeutic agent for OAB with fewer adverse effects (7 -10) . We previously demonstrated that imidafenacin bound muscarinic receptors in the human 4), indicating a close correlation between the binding affinity of imidafenacin to bladder muscarinic receptors and its pharmacological effects in the bladder. Previous studies (2, 12, 14) showed that muscarinic receptors were present on not only detrusor but also urothelium, a epithelial lining of the urinary tract. The current study measured specific [ 3 H]imidafenacin binding in the human detrusor including the urothelium. Thus, this radioligand may bind muscarinic receptors in the urothelium as well as in the detrusor muscle.
Our previous study demonstrated that the affinity of imidafenacin to muscarinic receptors ([ 3 H]NMS binding sites) was 2.2 times higher affinity in the human parotid gland than in the bladder (12) . In the current study, the K d value for specific [ 3 H]imidafenacin binding in the human bladder was approximately 3 times higher than that in the parotid gland, suggesting the higher binding affinity of imidafenacin to muscarinic receptors in the human parotid gland.
The salivary gland predominantly contains M 3 muscarinic receptors (16, 17) , whereas the bladder contains both the M 2 and M 3 subtypes, with a predominance of M 2 receptors (18) . Furthermore, our previous study with M 1 -M 5 -receptor knockout mice revealed that expression of the M 3 subtype was higher in the salivary gland than in the bladder (19 (20) . Consistent with these findings, the predominance of the M 3 receptor in the human parotid gland was demonstrated directly by a radioligand binding assay using N-(2-chloroethyl)-4-piperidinyl diphenylacetate (4-DAMP mustard), an irreversible inactivating agent of the M 3 subtype (14) . Since imidafenacin exhibited greater selectivity for the M 3 than M 2 subtype in CHO-K1 cells expressing human muscarinic receptors (4), the high affinity of [ 3 H]imidafenacin for muscarinic receptors in the human parotid gland reflects M 3 -subtype selectivity. In vivo functional and ex vivo muscarinic receptor binding experiments in rats (5, 6) and clinical studies in humans (9, 10) showed that imidafenacin selected the bladder over the exocrine gland. These in vivo results appear to contradict the M 3 -subtype selectivity observed in vitro, but in vivo bladder selectivity has been mainly attributed to the pharmacokinetic property of this agent (6) . Orally administered imidafenacin was shown to be distributed at a higher concentration in the bladder of rats than in the salivary gland (6) . Our preliminary results showed that imidafenacin might distribute to the bladder tissue from the urine as well as the circulating blood. Such predominant distribution from the urine may contribute to the bladder selectivity over the salivary gland.
Interestingly unlabeled imidafenacin as well as the clinically used antimuscarinic agents, oxybutynin, tolterodine, and solifenacin, competed with [ 3 H]imidafenacin for binding sites in the human bladder in a concentration-dependent manner, which indicated the pharmcological specificity of [ 3 H]imidafenacin binding sites. Figure 4 shows the strong correlation between the inhibitory potencies (pK i ) of specific [ ]imidafenacin over these radioligands may be more selective to the M 3 subtype of muscarinic receptors.
In conclusion, the current study is the first to provide direct evidence to demonstrate that imidafenacin bound muscarinic receptors in the human bladder, supporting its clinical relevance as a useful therapeutic agent for OAB. [ 3 H]Imidafenacin may also be a useful radioligand for labeling the M 3 subtype of muscarinic receptors with higher selectivity than other radioligands. (Table 1) . Pharmacological data [pA2 values for the competitive inhibition of carbachol-induced contractions of isolated bladder tissues from humans (closed circle), guinea pigs (closed triangle), or rats (closed square)] were quoted from the literature (4, 15, 21 -23) . pKi values for 4 antimuscarinic agents of bladder [ 3 H]imidafenacin binding were significantly (P < 0.01, Spearman test) correlated with their pharmacological properties (pA2). The correlation coefficient for this relationship was r = 0.90.
